Smith & Nephew Investors - SN.

Best deals to access real time data!
Silver Monthly Subscription for only ~~£17.37~~
Level 2 Basic Monthly Subscription for only ~~£62.08~~
UK/US Silver Monthly Subscription for only £30.59
VAT not included

Stock Name	Stock Symbol	Market	Stock Type	Stock ISIN	Stock Description
Smith & Nephew Plc	SN.	London	Ordinary Share	GB0009223206	ORD USD0.20

	Price Change	Price Change %	Stock Price	Last Trade
	7.00	0.5%	1,407.50	15:15:44

Open Price	Low Price	High Price	Close Price	Previous Close
1,402.00	1,393.50	1,409.50		1,400.50

more quote information »

Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Top Investor Posts

Date	Subject
10/5/2020 09:36	philanderer: MIDAS SHARE TIPS: Hip replacement company Smith & Nephew can ease the pain of lockdown for investors https://www.dailymail.co.uk/money/investing/article-8303561/MIDAS-SHARE-TIPS-Smith-Nephew-ease-pain-lockdown.html Read Full Thread Follow Reply
22/1/2018 10:16	basil brush1: Good luck! IMO these UK companies that report in foreign currencies lose out both ways, because the US investors dont understand the accounting while the UK investors are confused by the currency. SN has fallen nearly £2 since October, the market seems to be discounting the worst. But meanwhile Stryker keeps marching on. Read Full Thread Follow Reply
31/5/2016 09:39	broadwood: And takeover prospects in for nothing. Also offering an outlook less positively correlated with the UK economy than most of its index peers is Smith & Nephew (LSE: SN). It has the added advantage over most stocks (including AstraZeneca) in that its business model is very consistent and reliable. In fact, Smith & Nephew has been able to increase its earnings in each of the last five years and with earnings growth of 2% pencilled-in for this year as well as 12% for next year, investor sentiment towards the company could improve. That’s especially the case since Smith & Nephew trades on a price-to-earnings growth (PEG) ratio of only 1.4, which indicates that its shares offer strong growth prospects at a very reasonable price. Read Full Thread Follow Reply
22/12/2015 10:51	broadwood: Medical play shoots skywards Prosthetic joint builder Smith & Nephew (LSE: SN) has also enjoyed a splendid bump higher during the past week, the stock having added 9% between Monday and Friday. And I believe the London business can continue pulling away from its recent 12-month lows as growth investors pile in. Smith & Nephew received a shot in the arm last week thanks to rumours that Stryker was poised to launch a £12.1bn takeover attempt. The US-based medical firm is flush with cash and has apparently appointed Goldman Sachs to advise on a potential deal. And I believe Smith & Nephew is certainly worth the fuss. Demand for the company’s synthetic body parts continues to explode, particularly in the white-hot North American market. Meanwhile acquisitions in developed and emerging regions alike should significantly bolster sales in the years ahead. Smith & Nephew is expected to recover from an anticipated 4% earnings fall in 2015 with a 10% rise next year, resulting in a P/E rating of 19.1 times. I believe the firm’s improving position in a rapidly-expanding market fully warrants such a rating. Read Full Thread Follow Reply
05/3/2015 10:33	mike740: Smith & Nephew plc Stock Rating Reaffirmed by Sanford C. Bernstein (SN) March 3rd, 2015 Updated 5th March 2015 Smith & Nephew plc (LON:SN)‘s stock had its “outperform221; rating restated by investment analysts at Sanford C. Bernstein in a note issued to investors on Tuesday. They currently have a GBX 1,350 ($20.80) target price on the stock. Sanford C. Bernstein’s target price would suggest a potential upside of 12.68% from the company’s current price. Shares of Smith & Nephew plc (LON:SN) traded down 5.34% during mid-day trading on Tuesday, hitting GBX 1135.00. The stock had a trading volume of 11,677,271 shares. Smith & Nephew plc has a one year low of GBX 858.50 and a one year high of GBX 1211.00. The stock’s 50-day moving average is GBX 1180. and its 200-day moving average is GBX 1093.. The company’s market cap is £10.136 billion. Several other analysts have also recently commented on the stock. Analysts at Numis Securities Ltd reiterated a “hold” rating and set a GBX 1,105 ($17.03) price target on shares of Smith & Nephew plc in a research note on Monday. Analysts at AlphaValue reiterated a “buy” rating and set a GBX 1,399 ($21.56) price target on shares of Smith & Nephew plc in a research note on Friday. Analysts at Cenkos Securities Ltd reiterated a “buy” rating and set a GBX 1,200 ($18.49) price target on shares of Smith & Nephew plc in a research note on Thursday, February 12th. Finally, analysts at Berenberg Bank raised their price target on shares of Smith & Nephew plc from GBX 990 ($15.26) to GBX 1,080 ($16.64) and gave the company a “hold” rating in a research note on Monday, February 9th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of GBX 1,107.59 ($17.07). Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (LON:SN) and advanced wound management. It operates in three segments: Orthopaedics, Endoscopy and Advanced Wound Management. Read Full Thread Follow Reply
14/1/2011 23:02	harvester: This has been a bizarre sequence of events surrounding Sn. First came the news report by Sky concerning a bid approach by J&J last december, allegedly at 750 and rejected by the company. That led to wild bid speculation and rumours of renewed bid activity. That was not confirmed by the company which kept silent. The next day there were press reports that the FSA was investigating possible market manipulation surrounding Sn. and its shares. Hence the share price which had jumped by 80 on day 1 fell back by 50-60 . Then today the share price jumped up again above 700, possibly due to a finance page article in the Times(correction: D Telegraph) claiming current merger discussions with Biomet with exact financial details on how this can be financed and achieved. However, within hours the share price fell back again today, presumably in response to an RNS announcement by Sn. that they are not involved in merger or takeover talks contrary to press speculation . It looks like the FSA needs to dig a bit deeper and with some urgency to trace the rumour mongers and their attempts of market manipulation . Meanwhile long-term investors may see opportunities of profitable exit and re-entry at a lower price. Enjoy the ride . Read Full Thread Follow Reply
11/1/2011 15:54	losses: Smith & Nephew is warned over Johnson & Johnson deal as shares hit new high By Simon Duke Last updated at 11:19 AM on 11th January 2011 Smith & Nephew was last night facing calls to come clean with shareholders after takeover rumours propelled shares in the British hip and knee replacement maker to an all-time high. In an apparent breach of Britain's takeover rules, S& N declined to shed any light on speculation that the FTSE 100 group had rebuffed a £7bn approach from US medical giant Johnson & Johnson last month. Weekend reports suggested that J&J, best known for its baby lotions and talcum powder, was considering raising its 750p-ashare bid sent S&N stock rocketing by as much as 13 per cent yesterday. Cash injection: The Mail reported a bid for S&N, but the firm hasn't disclosed takeover approaches Cash injection: The Mail reported a bid for S&N, but the firm hasn't disclosed takeover approaches It is the second time in a matter of weeks that the shares have risen sharply on the back of takeover rumours. Last month the Daily Mail reported that Hullbased S&N had received an 800pa-share takeover bid, triggering a near 10 per cent jump in its share price that day. Yet S&N (up 62p to 712.5p) has so far resisted the mounting pressure for complete transparency - despite Takeover Panel rules that require companies to keep investors informed of possible offers. Under the watchdog's Takeover Code, listed firms are obliged to disclose takeover approaches that leak into the public domain or cause an 'untoward' surge of more than 10 per cent in a company's share price. S&N's decision to maintain complete radio silence was met with incredulity by groups representing private investors. Eric Chalker of the UK Shareholder's Association said: 'It would seem to be strange behaviour on the part of the Board.' 'It must be questionable whether they're keeping the interests of all shareholders at the top of their agenda.' 'There will always be differences of opinion between investors- be they private, institutional or short term. 'This makes it all the more important that all shareholders have the same information to make their investment decisions.' It is understood that S&N has exploited a provision in the Takeover Code, which says that firms are not bound by the disclosure rules if they believe a spurned suitor won't return with a sweetened offer. One of S&N's top ten institutional investors told the Mail that S&N chairman John Buchanan was right not to disclose the putative bid from J&J. 'Having to disclose every speculative bid can be very disruptive both for staff and management,' the veteran fund manager said. 'Why should the Board have to put out this information under duress when they consider the price to be inadequate?' he asked. Analysts said J&J would have to table a firm offer of at least 900p a share to win over S&N investors. Read more: http://www.dailymail.co.uk/money/article-1345905/Smith-amp-Nephew-warned-Johnson-amp-Johnson-deal-shares-propelled-new-hight.html#ixzz1Ak6ctVpq Read Full Thread Follow Reply
10/1/2011 01:53	spob: S&N risks investor anger over takeover offer By Miles Johnson in London and Helen Thomas in New York FT 9 Jan 2011 Smith & Nephew has risked criticism from its investors after rejecting a £7bn takeover offer without making the information public, becoming the second large UK company to do so in recent months. Johnson & Johnson, the US healthcare group, approached Smith & Nephew late last year but its offer was knocked back by the hip-and-knee replacement manufacturer's board as too low. The offer, which people close to the FTSE 100 company believe to be priced at about 750p-800p a share, came at a similar time to when sustained takeover speculation pushed Smith & Nephew shares up by 14 per cent over December. They closed at 650p last week. It is not clear whether Johnson & Johnson would return with improved terms at a later date, these people said. Smith & Nephew has been a perennial target for takeover talk over the past decade owing to its position as one of the smaller players in the medical devices market, a maturing industry where global players are at an advantage. The UK's takeover watchdog can force a group to confirm a takeover approach if speculation has an unusual effect on its share price. The company could now be forced to make a statement to the market as early as Monday. Smith & Nephew on Sunday said it was against company policy to comment on "market speculation". "We are aware of our obligations, and the board is entirely focused on the creation of shareholder value," it said. Johnson & Johnson declined to comment. News of the approach comes after the banknote printer De La Rue was criticised by some of its shareholders for failing to disclose an approach from France's Oberthur Technologies. The distraction to day-to-day business caused by takeover approaches means companies can be reluctant to inform their investors when they reject an offer. One UK institutional investor said: "Management teams sometimes have a vested interest in keeping approaches secret. I think a company's shareholders should be allowed to make their own decision." While Johnson & Johnson was one logical buyer of Smith & Nephew, industry bankers said the company would be likely to attract more interest. A combination with Biomet, the Indiana-based producer of replacement hips, knees and shoulders which was taken private in 2006 by Blackstone, Goldman Sachs, KKR and TPG, is a possibility. Read Full Thread Follow Reply
09/1/2011 11:10	cool runnings: Smith & Nephew, the FTSE 100 manufacturer of hip and knee replacements, has received a £7bn takeover approach from Johnson & Johnson, its US-based rival, I can reveal. An indicative offer valuing Smith & Nephew (S&N), one of the world's largest orthopaedics-makers, at more than 750p-a-share was tabled with the company several weeks before Christmas, I'm told. The approach from Johnson & Johnson (J&J) was discussed by board members at S&N before being rejected on the basis that it substantially undervalued the company. I understand that the American company has been evaluating whether to return with a higher offer although there's no certainty that it will do so. News of the approach raises once again the prospect of a major British company being swallowed by an overseas rival. That would no doubt attract political attention, particularly from Vince Cable, the Business Secretary, who has commissioned a review of issues such as the efficacy of Britain's laissez-faire takeover regime in the wake of Cadbury's sale to Kraft Foods. S&N is a world leader in its field and specialises in advanced wound-care products such as dressings and gels, endoscopy and other medical devices, as well as its orthopaedics business. S&N's shares have been inflated by persistent takeover speculation in recent months, and shot up by 9 per cent during one trading session alone in early December. Yesterday, however, the shares slipped 1.9 per cent to close at 650p after S&N's privately-owned rival, Biomet, reported that sales growth had slowed and that pricing had become tougher for the hip and knee implants it sells. At yesterday's closing price, S&N is valued at £5.74bn. Biomet, which is owned by a quartet of investment firms including the private equity arm of Goldman Sachs, has also been touted as a likely bidder for S&N. It's possible (perhaps even likely) that if J&J does return with a higher offer, that it would be tempted to enter the fray, although it would face significant financing constraints. Other competitors such as Stryker and Zimmer may also be interested in a bid. My disclosure that S&N did in fact receive a takeover approach before Christmas is likely to raise the issue of why it was not disclosed to the stock market despite such protracted speculation. S&N and its advisers would probably argue that since much of that speculation centred on the wrong bidder (Biomet rather than J&J), there was no need to confirm the approach in a public statement. It's not hard to understand why boards prefer not to confirm takeover offers that they have already turned down. A prolonged period of having to publicly fend off suitors causes uncertainty for employees and distracts management from concentrating on running their company. Nonetheless, investors may look at a similar situation at De La Rue, the banknote printer, and feel aggrieved that they are not being given the appropriate opportunities to consider takeover approaches for the companies they own. I suspect that S&N will only issue a public statement confirming the approach from J&J if its share price moves materially on Monday morning. That said, there aren't too many other similarities between S&N and De La Rue. The orthopaedics-maker is performing well under David Illingworth, its chief executive, whereas the banknote printer is going through a period of turmoil and facing the loss of its largest customer. Indeed, S&N beat analysts' expectations at its third-quarter results in November as a result of improved sales of its trauma therapy and wound-care products. The company also cheered the City by promising to increase its investment in growth markets such as China and India. S&N declined to comment today on the takeover approach, while J&J could not be reached for comment. Read Full Thread Follow Reply
21/7/2010 12:46	offler: "which is likely to lead investors to believe market growth is slowing." Well then SN should undertake aggressive market increase tactics - break some old peoples legs. Read Full Thread Follow Reply

Advertise Here

Your Recent History

LSE

SN.

Smith & Ne..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20210413 14:31:12